Literature DB >> 31322423

Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease.

Joosep Kalamägi1, Piia Lavikainen1, Heidi Taipale1,2, Antti Tanskanen3,4, Jari Tiihonen3,4, Sirpa Hartikainen1,2, Anna-Maija Tolppanen1.   

Abstract

Objectives: We studied the determinants of high healthcare costs (highest decile of hospital care and medication costs) and cost trajectories among all community-dwellers with clinically verified Alzheimer's disease (AD), diagnosed during 2005-2011 in Finland (N = 70,531).
Methods: The analyses were done separately for hospital care costs, medication costs and total healthcare costs that were calculated for each 6-month period from 5 years before to 3 years after AD diagnosis.
Results: Total healthcare costs were driven mainly by hospital care costs. The definition of "high-cost person" was time-dependent as 63% belonged to the highest 10% at some timepoint during the study period and six distinct cost trajectories were identified. Strokes, cardiovascular diseases, fractures and mental and behavioural disorders were most strongly associated with high hospital care costs. Conclusions: Although persons with AD are often collectively considered as expensive patient group, there is large temporal and inter-individual variation in belonging to the highest decile of hospitalization and/or medication costs. It would be important to assess whether hospitalization rate could be decreased by, e.g., comprehensive outpatient care with more efficient management of comorbidities. In addition, other interventions that could decrease hospitalization rate in persons with dementia should be studied further in this context. Key messages Persons with AD had large individual fluctuation in hospital care costs and medication costs over time. Hospital care costs were considerably larger than medication costs, with fractures, cardiovascular diseases and mental and behavioural disorders being the key predictors. Antidementia medication was associated with lower hospital care costs.

Entities:  

Keywords:  Alzheimer’s disease; costs; hospitalization; medications; trajectory analyses

Mesh:

Year:  2019        PMID: 31322423      PMCID: PMC7877886          DOI: 10.1080/07853890.2019.1642507

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   5.348


  26 in total

1.  Pharmacotherapy of dementia in Germany: Results from a nationwide claims database.

Authors:  Jens Bohlken; Mandy Schulz; Michael A Rapp; Jörg Bätzing-Feigenbaum
Journal:  Eur Neuropsychopharmacol       Date:  2015-10-03       Impact factor: 4.600

Review 2.  Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America.

Authors:  Claire Takizawa; Paula L Thompson; Anneloes van Walsem; Céline Faure; William C Maier
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients.

Authors:  Anders Gustavsson; Per Brinck; Niklas Bergvall; Katarzyna Kolasa; Anders Wimo; Bengt Winblad; Linus Jönsson
Journal:  Alzheimers Dement       Date:  2011-05       Impact factor: 21.566

4.  Cost of Alzheimer's disease and related dementia in managed-medicare.

Authors:  E M Gutterman; J S Markowitz; B Lewis; H Fillit
Journal:  J Am Geriatr Soc       Date:  1999-09       Impact factor: 5.562

5.  Hospital admissions, outpatient visits and healthcare costs of community-dwellers with Alzheimer's disease.

Authors:  Anna-Maija Tolppanen; Heidi Taipale; Timo Purmonen; Marjaana Koponen; Hilkka Soininen; Sirpa Hartikainen
Journal:  Alzheimers Dement       Date:  2014-12-10       Impact factor: 21.566

6.  2016 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2016-04       Impact factor: 21.566

7.  Implications of comorbidity on costs for patients with Alzheimer disease.

Authors:  Tzu-Chun Kuo; Yang Zhao; Sharada Weir; Marilyn Schlein Kramer; Arlene S Ash
Journal:  Med Care       Date:  2008-08       Impact factor: 2.983

8.  Drug expenditure of high-cost patients and their characteristics in Finland.

Authors:  Leena K Saastamoinen; Jouko Verho
Journal:  Eur J Health Econ       Date:  2012-05-12

9.  Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer's disease in a Finnish nationwide cohort.

Authors:  Heidi Taipale; Maija Purhonen; Anna-Maija Tolppanen; Antti Tanskanen; Jari Tiihonen; Sirpa Hartikainen
Journal:  Scand J Public Health       Date:  2015-11-09       Impact factor: 3.021

10.  Health-related quality of life and socioeconomic status: inequalities among adults with a chronic disease.

Authors:  Andreas Mielck; Martin Vogelmann; Reiner Leidl
Journal:  Health Qual Life Outcomes       Date:  2014-04-25       Impact factor: 3.186

View more
  1 in total

1.  SOCS1 Mediates Berberine-Induced Amelioration of Microglial Activated States in N9 Microglia Exposed to β Amyloid.

Authors:  Qi Guo; Chen Wang; Xiaorong Xue; Bin Hu; He Bao
Journal:  Biomed Res Int       Date:  2021-11-05       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.